Dr. Eigl is a medical oncologist specializing in genitourinary oncology, with a special research interest in bladder and prostate cancers.  He presently leads several clinical trials evaluating novel therapies such as antisense oligonucleotides and oncolytic viruses in these disease settings.  He is active in national and international clinical trials and is a member of the National Cancer Institute of Canada GU Clinical Trials Group and Canadian Uro-Oncology Group.

Dr. Ralph Buttyan is a Senior Scientist in the Vancouver Prostate Centre and has been involved in prostate cancer research for over 28 years. He recently joined the Prostate Centre from New York, USA, where he was Professor in Pathology and Urology at Columbia University and a Senior Scientist at the Ordway Research Institute.

The primary focus of Dr. Ong's research program is to understand the molecular mechanisms that govern the progression of prostate cancer from a state of androgen sensitivity to hormone independence with the hope of developing novel therapeutic strategies to prevent or delay the progression of prostate cancer to androgen independence. His primary focus has been on the PTEN tumour suppressor gene, which is among the most frequently mutated genes in cancer.

Dr. Nelson’s research interests focus on changes in gene expression in androgen-independence of prostate cancer, and use of high-throughput bioprofiling for screening, validation, and functional evaluation of targets.  This is a key initial step in converting genes from leads to targets and on to products with commercial values.  In collaboration with Dr. Gleave, she has brought several genes from discovery to licensing.  Together with Drs.

Dr. Chi is a medical oncologist with the BC Cancer Agency who, at a relatively early stage in his career, has received national and international recognition for his contributions to prostate cancer research. Dr. Chi's research is focused in the area of genitourinary cancers with a special interest in prostate cancer and investigational new drugs.  This includes phase I, II and III clinical trials, therapeutic use of antisense oligonucleotides and mechanisms of treatment resistance. He holds peer reviewed grant funding from the National Cancer Institute of Canada (NCIC), The U.S.

Dr. Ben Chew is originally from Duncan, BC, graduated from UBC Medicine in 1998 and completed his urology residency at the University of Toronto in 2003.  His fellowship focused on kidney stones and minimally invasive surgery at the University of Western Ontario.  He has been on active staff at VCH since July 2006 where he is an Assistant Professor in the Department of Urologic Sciences.  Dr. Chew’s research focuses on how kidney stones form and in particular intestinal absorption of minerals that can form kidney stones (calcium and oxalate).

In 1967, Dr. Bruchovsky discovered that dihydrotestosterone is the active form of testosterone, the principal male sex hormone produced by the testis. At the time of this discovery, he was working with Dr. Jean D. Wilson at the Southwestern Medical School in Dallas, Texas. The report of these experimental results was published in the Journal of Biological Chemistry and became a Current Contents Citation Classic. Also Dr.

Dr. Amina Zoubeidi’s ongoing research efforts focus on signal transduction mediated regulation of prostate cancer progression, with emphasis on the importance of heat shock proteins and kinases, and applying that research to develop and investigate novel therapeutic strategies to fight advanced prostate cancer.

Dr Collins is a senior scientist at the Vancouver Prostate Centre and a Director of The Laboratory for Advanced Genome Analysis (LAGA). In addition, he is an associate adjunct professor at the University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center and a visiting scientist at Lawrence Berkeley National Laboratory. He has held positions at Lawrence Livermore National Laboratory and Lawrence Berkeley National Laboratory at UCSF.

Dr. Michael Cox is a molecular and cellular biologist who earned his PhD in Biochemistry from the University of North Carolina for studies on how oncogenes impact neuronal growth and differentiation. He began his work on cell signaling networks in prostate cancer at the University of Virginia. His research program is dedicated to understanding how prostate cancer, the most frequently diagnosed male malignancy, initiates and progresses and to finding ways of halting advanced disease progression.